Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Dec 5;5(4):zcad057. doi: 10.1093/narcan/zcad057

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023. Published by Oxford University Press on behalf of NAR Cancer.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 5. — Low DDB2 levels predict better survival of oxaliplatin-treated colon cancer patients. Kaplan–Meier analysis shows association of tumor DDB2 mRNA levels with overall survival in (A)108 colon cancer TCGA patients clinically treated with oxaliplatin, (B) a subset of 87 patients diagnosed with colon cancer at TNM stage III and IV and clinically treated with oxaliplatin, and (C) a different group of 38 colon cancer patients clinically treated with regimens not containing oxaliplatin. (D) Kaplan-Meier analysis of association of tumor DDB2 expression levels with overall survival of patients diagnosed with cisplatin-treated cancers including lung cancer, (E) cervical cancer and (F) ovarian cancer. Each graph shows the mRNA level cut off leading to the best separation of the groups, the number of patients in each group and the P-value obtained in the logrank test.